Last reviewed · How we verify
Placebo for IVIG
Placebo for IVIG is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for Control arm in Phase 3 trial for IVIG-responsive conditions (specific indication not specified).
A placebo control contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo control contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 trial for IVIG-responsive conditions (specific indication not specified).
At a glance
| Generic name | Placebo for IVIG |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-based response). In this case, it serves as the control arm in a Phase 3 trial comparing against intravenous immunoglobulin (IVIG).
Approved indications
- Control arm in Phase 3 trial for IVIG-responsive conditions (specific indication not specified)
Common side effects
- Adverse events expected to reflect natural disease progression or trial-related procedures only
Key clinical trials
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome (PHASE2)
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (PHASE2)
- Add-on Intravenous Immunoglobulins in Early Myositis (PHASE2, PHASE3)
- The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy (PHASE2)
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- IVIG for Infection Prevention After CAR-T-Cell Therapy (PHASE2)
- Outpatient Treatment With Anti-Coronavirus Immunoglobulin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for IVIG CI brief — competitive landscape report
- Placebo for IVIG updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Placebo for IVIG
What is Placebo for IVIG?
How does Placebo for IVIG work?
What is Placebo for IVIG used for?
Who makes Placebo for IVIG?
What development phase is Placebo for IVIG in?
What are the side effects of Placebo for IVIG?
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Control arm in Phase 3 trial for IVIG-responsive conditions (specific indication not specified)
- Compare: Placebo for IVIG vs similar drugs
- Pricing: Placebo for IVIG cost, discount & access